Clinical experience in using long-acting human insulin Glargine 300 U/ml in the practice of an endocrinologist
https://doi.org/10.21518/2079-701X-2018-6-128-131
Abstract
Diabetes mellitus (DM) is a severe chronic disease which prevalence continues to increase steadily worldwide. According to the latest data, the number of patients with DV worldwide has more than doubled over the past 10 years and by the end of 2015 reached 415 million people. The government expenditure on the treatment of patients who have developed diabetes complications significantly outweigh the expenditure on patients without complications. Timely diagnosis, efficient and safe modern therapy, including insulin therapy with the use of next generation insulin, make it possible to optimize control over the economic burden of DM.
About the Authors
O. A. GusevaRussian Federation
A. A. Nelaeva
Endos Diagnostic Center, Tyumen
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
E. A. Aleksandrova
Russian Federation
PhD in medicine
Yu. V. Khasanova
Tyumen State Medical University
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Ametov AS. Type 2 diabetes mellitus. Problems and solutions. M.: Geotar-Media, 2011: 254-287.
2. Antsiferov MB. Innovative Combined Drug Galvumet (Vildagliptin/Metformin hydrochloride) for the Treatment of Type 2 Diabetes Mellitus. Pharmacy, 2009, 17: 30-35.
3. Ametov AS, Chernikova NA, Antsiferov MB. Basal Insulin Therapy: Experience in Clinical Practice. Farmateka, 2013, 16: 37-41.
4. Kuraeva TL. Insulin analogues in achieving the compensation and improving the quality of life of children and adolescents with type 1 diabetes. Sakharny Diabet, 2010, 3: 147-152.
5. Nikonova TV. The 2015 ADA Congress in Boston (USA): overview of the main topics. Sakharny Diabet, 2015, 18 (3): 110-113.
6. Ametov AS, Chernikova NA. New potential of modern basal insulin therapy for the treatment of patients with type 1 diabetes and type 2 diabetes: translating clinical trials into actual practice. M.: GEOTAR-MEDIA, 2016. 3: 1-7.
7. Antsiferov MB. Clinical characteristics and practical aspects of the use of a new basal insulin analogue glargine 300 U/ml Toujeo; SoloStar. Farmateka, 2016, 16: 1-5.
8. Algorithms for specialized medical care in diabetes mellitus. 8th Issue. Edited by Dedova ІІ, Shestakova MV, Mayorova AYu. 2017: 1-112.
9. Patient Information Leaflet for Medicinal Products for Human Use Toujeo Solostar. RU LP-003653, dated May 30, 2017.
10. Patient Information Leaflet for Medicinal Products for Human Use Glimepiride. P N015530 / 01-131216.
11. Patient Information Leaflet for Medicinal Products for Human Use Metformin.
12. Belousov DYu, Afanasyeva EV. Evaluation of the cost-effectiveness of a new insulin analogue of glargine in type 2 diabetes mellitus. Kachestvennaya Klinicheskaya Praktika, 2016, 2: 5-13.
13. Belousov DYu, Zyryanov SK. Clinical and economic analysis of basal insulin analogues in type 2 diabetes mellitus under real-life conditions. Kachestvennaya Klinicheskaya Praktika, 2012, 2: 22-32.
14. Dedov II, Shestakova MV, Ametov AS et al. Consensus of the Council of Experts of the Russian Association of Endocrinologists on the initiation and intensification of sugar suppressing therapy in patients with type 2 diabetes mellitus. Sakharny Diabet, 2011, 1: 95-105.
15. Glinkina IV. LOTUS2: Observational study of the efficacy and safety of insulin glargine (luntus) therapy in the daily clinical practice of patients with type 2 diabetes who have not reached the target glycemic control on detemir insulin therapy. Problemy Endokrinologii, 2013, 59: 25-31.
16. Dedov II, Omelyanovsky VV, Shestakova MV et al. Diabetes mellitus as an economic problem in the Russian Federation. Sakharny Diabet, 2016, 1: 30-43.
Review
For citations:
Guseva OA, Nelaeva AA, Aleksandrova EA, Khasanova YV. Clinical experience in using long-acting human insulin Glargine 300 U/ml in the practice of an endocrinologist. Meditsinskiy sovet = Medical Council. 2018;(6):128-131. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-128-131
Views:
770
Email this article 